Scott Megill is President and Chief Executive Officer of Coriell Life Sciences (CLS). With a vision to translate decades of cutting-edge genetic research into insights that empower the most precise medical care, Scott launched Coriell Life Sciences out of the renowned Coriell Institute for Medical Research in 2013. Under his leadership, CLS has grown to become an internationally trusted provider of bioinformatics, genetic interpretation and reporting, and comprehensive medication risk management solutions. Pioneering innovation in precision medicine, Scott is a driving force in setting the industry standard for pharmacogenomics and advancing a healthier world.
An entrepreneurial leader recognized for unlocking the power of technology to fuel smarter healthcare, Scott is spearheading the world’s first precision medicine approach to COVID-19 testing. By leveraging advanced infrastructure developed for pharmacogenomics reporting, Scott is consulting with employers and large organizations to deliver one of the only scalable and intelligent COVID-19 testing solutions for large enterprises in the U.S. and globally.
Scott previously served as CIO at the Coriell Institute for Medical Research and held IT leadership roles at Dow Chemical Company and Rohm and Haas. He also founded the Moorestown Robotics Club, an organization that immerses elementary, middle, and high school students in the excitement of science and technology through international robotics competitions.
Scott holds an Executive Master of Business Administration degree from Villanova University and a Bachelor of Arts degree in English and Philosophy from Drew University.